Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GSK159802 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Subjects receiving treatment sequence 1 : Cohort 1 | EXPERIMENTAL | Eligible subjects will receive placebo, GSK159802 300 micrograms, GSK159802 600 micrograms, GSK159802 900 micrograms and GSK159802 1200 micrograms. |
| Subjects receiving treatment sequence 2 : Cohort 1 | EXPERIMENTAL | Eligible subjects will receive GSK159802 150 micrograms, placebo, GSK159802 600 micrograms, GSK159802 900 micrograms and GSK159802 1200 micrograms. |
| Subjects receiving treatment sequence 3 : Cohort 1 | EXPERIMENTAL | Eligible subjects will receive GSK159802 150 micrograms, GSK159802 300 micrograms, placebo, GSK159802 900 micrograms and GSK159802 1200 micrograms. |
| Subjects receiving treatment sequence 4 : Cohort 1 | EXPERIMENTAL | Eligible subjects will receive GSK159802 150 micrograms, GSK159802 300 micrograms, GSK159802 600 micrograms, placebo and GSK159802 1200 micrograms. |
| Subjects receiving treatment sequence 5 : Cohort 1 | EXPERIMENTAL | Eligible subjects will receive GSK159802 150 micrograms, GSK159802 300 micrograms, GSK159802 600 micrograms, GSK159802 900 micrograms and placebo. |
| Subjects receiving treatment sequence 1 : Cohort 2 | EXPERIMENTAL | Eligible subjects will receive placebo, salmeterol, GSK159802 low dose (LD) and GSK159802 maximum tolerated dose (MTD). |
| Subjects receiving treatment sequence 2 : Cohort 2 | EXPERIMENTAL | Eligible subjects will receive salmeterol, GSK159802 MTD, placebo and GSK159802 LD. |
| Subjects receiving treatment sequence 3 : Cohort 2 | EXPERIMENTAL | Eligible subjects will receive GSK159802 LD, placebo, GSK159802 MTD and salmeterol. |
| Subjects receiving treatment sequence 4 : Cohort 2 | EXPERIMENTAL | Eligible subjects will receive GSK159802 MTD, GSK159802 LD, salmeterol and placebo. |
| Subjects receiving treatment sequence 1 : Cohort 3 | EXPERIMENTAL | Eligible subjects will receive placebo, salmeterol, GSK159802 300 micrograms and GSK159802 1200 micrograms. |
| Subjects receiving treatment sequence 2 : Cohort 3 | EXPERIMENTAL | Eligible subjects will receive salmeterol, GSK159802 1200 micrograms, placebo and GSK159802 300 micrograms. |
| Subjects receiving treatment sequence 3 : Cohort 3 | EXPERIMENTAL | Eligible subjects will receive GSK159802 300 micrograms, placebo, GSK159802 1200 micrograms and salmeterol. |
| Subjects receiving treatment sequence 4 : Cohort 3 | EXPERIMENTAL | Eligible subjects will receive GSK159802 1200 micrograms, GSK159802 300 micrograms, salmeterol and placebo. |
| Subjects receiving treatment sequence 5 : Cohort 3 | EXPERIMENTAL | Eligible subjects will receive GSK159802 1200 micrograms, salmeterol, GSK159802 300 micrograms and placebo. |
| Name | Type | Description |
|---|---|---|
| GSK159802 | DRUG | GSK159802 will be available with dosing strengths of 75 microgram per blister and 300 microgram per blister administered using DISKUS inhaler. |
| Placebo | DRUG | Subjects will receive placebo administered using DISKUS inhaler. |
| Salmeterol | DRUG | Salmeterol will be available with dosing strength of 50 micrograms per blister administered using DISKUS inhaler. |
Inclusion criteria: * Body mass index within the range 18.5-29.9 (kg/m2) * Current non-smokers who have not used any tobacco products in the 6-month period preceding the screening visit and have a pack history of \< 10 pack years. Additional criteria for Cohorts 2 and 3 only (Asthmatic Patients): ...
GSK159802 is an investigational small molecule being developed for chronic obstructive pulmonary disease (COPD). It is a respiratory therapeutic that has been studied in a Phase 1 clinical trial. The drug is not approved and remains in early clinical development.
GSK159802 is being developed by GSK plc, a pharmaceutical company traded on the stock exchange under the ticker GSK. The company conducted a Phase 1 clinical trial of the drug in the United Kingdom.
GSK159802 is in Phase 1 clinical development. It has completed one Phase 1 trial, which was a controlled study in healthy male subjects and asthmatics. The drug is investigational and has not been approved for any use.
GSK159802 has one completed clinical trial, identified as NCT00364273. This Phase 1 study enrolled 43 participants in the United Kingdom and evaluated the drug in healthy male subjects and asthmatics with chronic obstructive pulmonary disease.
GSK159802 is a small molecule therapeutic developed for respiratory conditions. Its specific molecular target has not been disclosed in available information, so the exact mechanism of action is not publicly detailed.